GlassScriptPhysician profile
Andrew J Drabick
NPI 1235262718
$2,327.07
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,499 · 2020: $425 · 2021: $179 · 2022: $16.01 · 2023: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $207.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $611.63 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $260.84 | 2019-2023 | Repatha |
| Astrazeneca Pharmaceuticals LP | $238.35 | 2019-2023 | Farxiga |
| Abbvie INC. | $194.09 | 2019-2023 | Ubrelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $115.75 | 2019-2020 | |
| Lilly USA, LLC | $85.17 | 2019-2023 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.51 | 2019-2023 | Jardiance |
| Amarin Pharma, INC. | $77.63 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $77.47 | 2019 | |
| Sanofi-Aventis U.S. LLC | $63.59 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $61.19 | 2019-2020 | |
| Abbott Laboratories | $45.09 | 2019-2023 | Freestyle Libre 3 |
| Arbor Pharmaceuticals, INC. | $44.07 | 2019-2020 | |
| Sanofi Pasteur INC. | $39.52 | 2019 | |
| Glaxosmithkline, LLC. | $31.84 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $28.06 | 2020 | |
| Currax Pharmaceuticals LLC | $26.99 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $25.90 | 2023 | Rexulti |
| Nalpropion Pharmaceuticals LLC | $25.89 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $25.76 | 2019 | |
| Pfizer INC. | $23.20 | 2019-2020 | |
| Eisai INC. | $22.21 | 2019 | |
| Astellas Pharma US INC | $19.04 | 2019 | |
| Dermira, INC. | $17.08 | 2020 | |
| Exact Sciences Corporation | $16.82 | 2023 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.94 | 2019 | |
| Antares Pharma, INC. | $14.75 | 2019 | |
| Jazz Pharmaceuticals INC. | $13.15 | 2021 | |
| Esperion Therapeutics, INC. | $12.98 | 2020 | |
| Promius Pharma LLC | $12.56 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Drabick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.